All News
RheumNow Podcast – Rheumatology Burnout (1.29.2021)
Dr. Jack Cush reviews this past week's journal articles and news features on RheumNow.com. Colchicine, vaccine rollout, risk of RA in endometriosis patients, tREACH trial, lupus nephritis news, rheumatology burnout and more.
Read Article
2020 Rheumatology Year in Review
2020 was historic, memorable and game-changing. Under the cloud of COVID-19, there were many significant and memorable advances and setbacks for the rheumatology world. In our accounting of most read articles for 2020, (not surprisingly) 17/20 were COVID-related.
Read Article
Rheumatology Round-Up with Drs. Kavanaugh & Cush
The Annual Review of Best ACR 2020 abstracts featuring Drs. Cush and Kavanaugh filmed on the last day of Virtual ACR 2020 Nov. 9, 2020. Watch now!
Read Article
Systemic Sclerosis and Physical Therapy
Systemic sclerosis (SSc) is a chronic fibrosing disease currently with no available cure.
Read Article
Systemic Sclerosis Rapid Onset Pulmonary Arterial Hypertension Pulmonary Capillary Hemangiomatosis
RWCS 2021 Poster Session by Dr. Jason Melehani, Stanford University
https://t.co/wfxiY2VqcN
Links:
Dr. John Cush RheumNow ( View Tweet)
Johns Hopkins & UCSF Scleroderma pts tested for Abs against telomerase & shelterin (TERF1); while rare in RA, myositis, controls; TERF1 Abs seen in 9% of SSc & assoc w/ severe lung disease (OR 2.4) & shorter telomere length. (TERF1 found in 7% of IPF) https://t.co/e5ai8uO4kK
Links:
Dr. John Cush RheumNow ( View Tweet)
Osteitis in Systemic Sclerosis is UNCOMMON. French study of 48 pts shows 54% w/ osteitis beneath digital tip ulcers. Pain (75%), erythema (73%), warmth (73%) & 65% had high CRP. X‐ray, CT‐scans or MR. Antibiotics were 1st line therapy. https://t.co/o58gwq2SCC
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @ATSCPAssembly : Dr. Dinesh Khanna ( @sclerodermaUM): In post-hoc analysis of focuSSed trial of tocilizumab vs. placebo, disease duration, male gender, elevated acute phase reactants, and anti-SCL-70 Ab have a larger beneficial effect on FVC in early SSc-ILD.
Dr. John Cush RheumNow ( View Tweet)
Systemic Steroids Seldom Flare Psoriasis
https://t.co/14iz3l6CNf https://t.co/eiDXmoCitj
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @ejdein1 : Dr. Khanna NOVESA study #ACR20 Abst#L09. Autotaxin inhibitor ZIRI in early dcSSc. 21 pts ziri vs 12 PBO. mRSS at Wk24 mean difference -2.8. Ziri well-tolerated. Would be great for new drug for early SSc skin. @RheumNow. https://t.co/TOS9fp4gGK https://t.co/4SDisedzs3
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @TheLancetRheum: Results of the NOVESA phase 2 trial of Ziritaxestat in patients with diffuse cutaneous #SSc presented by @sclerodermaUM at #ACR20
Improvements in mRSS and ACR-CRISS with Ziritaxestat, but not in lung outcomes. https://t.co/GCZj64i86c https://t.co/Pd6qGEGOev
Links:
Dr. John Cush RheumNow ( View Tweet)
Quick Read: Systemic Sclerosis and Physical Therapy. by Dr. Sheila Marie Reyes ( @RHEUMarampa). #ACR20
https://t.co/CKhfPDhmPA https://t.co/bocUIJPBbD
Links:
Dr. John Cush RheumNow ( View Tweet)
Results of the NOVESA phase 2 trial of Ziritaxestat (an autotaxin inhibitor) in patients with diffuse cutaneous #SSc presented by @sclerodermaUM at #ACR20
Improvements in mRSS and ACR-CRISS with Ziritaxestat, but not in lung outcomes. 31/33 patients continue in OLE https://t.co/kVQWN1s8Zy
The Lancet Rheumatology TheLancetRheum ( View Tweet)
Dr. Khanna NOVESA study #ACR20 Abst#L09. Autotaxin inhibitor ZIRI in early dcSSc. 21 pts ziri vs 12 PBO. mRSS at Wk24 mean difference -2.8. Ziri well-tolerated. Would be great for new drug for early SSc skin. @RheumNow. https://t.co/qpvLFsAe0x
Eric Dein ejdein1 ( View Tweet)
Using National Inpatient Sample (NIS) claims, SSc pts hospitalized with acute MI (AMI) had a higher unadjusted inpatient mortality rate (9.17% vs. 4.68%; p=0.001)( (aOR=2.02) #ACR20 Abstr#1390 https://t.co/qWUMkJR40d
Dr. John Cush RheumNow ( View Tweet)
Nintedanib in rheum ILD (RA/SSc/CTD)
I appreciate the volumes might not seem like much, but:
- in first 1y Rx 20% more are spared a FVC decline>10%
- biggest diff in UIP-like pattern
With the right patient selection, nintedanib does have its place!
#ACR20 ABST1048/1049 @RheumNow https://t.co/jGZdR84bBU
David Liew drdavidliew ( View Tweet)
Racial disparity in SSc-ILD pts treated with MMF?
1️⃣Early initiation of MMF significantly slowed ⬇️ of FVC%
2️⃣No difference in MMF efficacy between African-Americans and non-AA
3️⃣AA had baseline lower FVC%
@RheumNow #ACR20 Abs0929 https://t.co/rtsbe7OCvA
Robert B Chao, MD doctorRBC ( View Tweet)
Interesting data re HCQ decreasing new PAH in Early SSc #scleroderma Not sure I believe it. Confounding, diff subsets get #hydroxycholoroquine due to inflammatory arthritis etc. Maybe a big pragmatic RCT is warranted as PAH is lethal @RheumNow @CRASCRRheum #ACR20 abstr#925 https://t.co/Al81sMGgxI
Janet Pope Janetbirdope ( View Tweet)
Hydroxychloroquine may reduce rate of progression of systemic sclerosis associated pulmonary hypertension when initiated early (<18 months).
Prospective, observational study.
@RheumNow #ACR2020 Abs#0925 https://t.co/nj0mNAY5Pe
Robert B Chao, MD doctorRBC ( View Tweet)
Please join #ACR20 for late breaking abstract on Ziritaxestat, selective autotaxin inhibitor. Phase 2a trial with stats significant effect on skin score and well tolerated. @UMIntMed
Session Date Monday, November 9
Presentation Time: 12:15 PM - 12:30 PM ET
Dr. Dinesh Khanna sclerodermaUM ( View Tweet)
